{"id":30374,"date":"2024-11-19T20:33:00","date_gmt":"2024-11-19T15:03:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30374"},"modified":"2024-11-19T20:34:10","modified_gmt":"2024-11-19T15:04:10","slug":"sitc-2024-conference-summary","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary","title":{"rendered":"SITC 2024 Summary: Quick Recap of what all happened during this year\u2019s annual meeting"},"content":{"rendered":"\n

The Society for Immunotherapy of Cancer i.e., SITC 2024 <\/strong>conference provided a comprehensive view into the latest innovations in cancer immunotherapy, including data on CAR T-cell therapies<\/a>, cancer vaccines<\/a>, bispecific and multispecific antibodies<\/a><\/strong>, along with next-generation cancer vaccines. Presentations from various pharmaceutical companies such as GlaxoSmithKline,<\/strong> Elicio Therapeutics, Palleon Pharmaceuticals, Novocure, Sapience Therapeutics, HUYABIO International, IO Biotech, Luminary Therapeutics, Innate Pharma, Nimbus Therapeutics, Immunomic Therapeutics, Agenus, Elicio Therapeutics, Oncotelic Therapeutics<\/strong>, Infinitopes, Xenetic Biosciences,<\/strong> Poseida Therapeutics<\/strong> and many others, emphasized the ongoing shift towards more personalized and targeted therapeutic approaches.\u00a0<\/p>\n\n\n\n

Checkpoint inhibitors<\/a><\/strong> continue to be a high-stakes area, with companies aiming to differentiate through next-generation molecules and novel combination regimens. This market sees major competition among Merck, Bristol-Myers Squibb<\/strong>, and now newer entrants like Palleon<\/strong> aims to capture niche patient segments with resistance to PD-(L) 1 therapies<\/a>, Elicio Therapeutics <\/strong>revealsdata of its cancer vaccine in high relapse risk KRAS mutated pancreatic ductal adenocarcinoma <\/strong>and colorectal cancer, Marengo\u2019s <\/strong>promising first-in-Human data for its Lead Program, Invikafusp Alfa, <\/strong>TCR \u03b2 chain-targeted bispecific antibody. Innate Pharma<\/strong> came up with its proprietary next generation\u00a0antibody-drug conjugate<\/a> (ADC) and innovative tetra-specific ANKET.<\/p>\n\n\n\n

In addition, for patients with advanced NSCLC, the results from the PERLA trial <\/strong>bring encouraging news. Currently, KEYTRUDA has dominated the NSCLC therapeutic landscape<\/strong> and has been a major revenue driver for Merck. However, as KEYTRUDA\u2019s<\/strong> patent is near its expiration in 2028, the market anticipates increased competition. The favorable outcomes observed with dostarlimab in the PERLA trial position it as a potential competitor in the NSCLC market<\/a>. In the trial, patients receiving the combination of dostarlimab <\/strong>and chemotherapy<\/strong> achieved a median overall survival <\/strong>of 20.2 months<\/strong>, noticeably longer than the 17.5 months observed in the pembrolizumab arm, potentially establishing dostarlimab as a preferred first-line treatment option. These developments will likely drive continued innovation, as companies vie to establish dominance in the immunotherapy field for lung cancer.<\/p>\n\n\n\n

Targeting the TME (Tumor Microenvironment)<\/strong> represents a new front in immunotherapy, with Novocure <\/strong>leading the charge alongside other companies exploring macrophage modulation and Treg targeting. Novocure\u2019s Tumor Treating Fields (TTFields) <\/strong>technology, combined with pembrolizumab<\/strong>, demonstrated impressive survival benefits in <\/strong>glioblastoma<\/strong><\/a> by creating an \u201cin-situ vaccination\u201d effect within the TME\u200b. This approach signals a new strategy to make otherwise immune-resistant tumors more accessible to immune responses.<\/p>\n\n\n\n

Late-breaking abstracts<\/strong> at the SITC 2024 conference showcased not only promising results but also data from failed trials. Among these were Merck\u2019s<\/strong> anti-TIGIT monoclonal antibody, vibostolimab<\/strong>, from the failed KEYVIBE-008<\/strong> study, which was featured as an oral presentation, and Arcus Biosciences <\/strong>and Gilead Sciences<\/strong>‘ anti-TIGIT mAb, domvanalimab<\/strong>, whose discontinued ARC-10<\/strong> trial was presented as a poster. Despite their setbacks, these trials provide critical insights into the challenges and opportunities in targeting TIGIT<\/strong>, a pathway still considered promising for combination immunotherapy approaches.<\/p>\n\n\n\n

Among other notable antibody-focused<\/strong> approaches, the conference included presentations highlighting advancements in CCR8 blockade<\/strong> and Claudin18.2 bispecifics<\/strong>, both of which remain hot areas of interest in pharma and biotech industry. The rise of CCR8 blockade has been low-key, but it has seen buy-in from major players like Amgen, Roche, AbbVie <\/strong>and Bristol Myers Squibb<\/strong>. The conference showcased results from a Phase I study of QLP2117<\/strong>, a CCR8-targeting mAb developed by China’s Qilu Pharmaceutical<\/strong>, in solid tumors. <\/p>\n\n\n\n

Claudin18.2 blockade<\/strong>, continues to draw significant attention, and now validated by Astellas’s<\/strong> recent approval of VYLOY (zolbetuximab-clzb) <\/strong>in Gastric Cancer<\/a>, continues to draw significant attention. Data on Q-1802<\/strong>, a Claudin18.2 x PD-L1 bispecific from QureBio<\/strong>, and givastomig<\/strong>, I-Mab’s Claudin18.2 x 4-1BB co-stimulated approach were presented at the conference.<\/p>\n\n\n\n

The CAR T-cell market is currently dominated by hematologic cancers<\/strong>, but data presented at the conference from various pharmaceutical companies reflects opportunities for CAR T-cells in solid tumors<\/strong>. Few of the notable examples include Fate Therapeutics’ <\/strong>FT825\/ONO-8250, an off-the-shelf, iPSC-derived CAR T-cell therapy candidate, for treating advanced solid tumors; Cellectis<\/strong>, which shared preclinical findings on enhancing CAR T-cell efficacy in solid tumors while reducing toxicity,whereas Poseida Therapeutics <\/strong>presented data on its Allogeneic CAR-T Cell Therapies.<\/strong><\/p>\n\n\n\n

Looking forward, it seems like, combination therapies<\/strong> and biomarker-driven approaches<\/strong> will dominate the next wave of immunotherapy. Top-abstracts presented during the meeting have been summarized in the table below:<\/p>\n\n\n\n

List of few top-abstracts presented at 2024 STIC Annual Meeting<\/strong><\/td><\/tr>
Drug Name<\/strong><\/td>Company Name<\/strong><\/td>Abstract Number<\/strong><\/td>Tittle<\/strong><\/td>Patient Segment<\/strong><\/td>Results<\/strong><\/td><\/tr>
Dostarlimab + chemotherapy<\/td>GlaxoSmithKline<\/td>711<\/td>Updated overall survival from PERLA, a phase II <\/strong>randomized double-blind trial of dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous non-small cell lung cancer (NSCLC)<\/td>Metastatic non-squamous non-small cell lung cancer (NSCLC)<\/td>Median OS was 20.2 months in the dostarlimab + CT arm vs 15.9 months in the pembrolizumab + CT armNo new safety signals were reported.<\/td><\/tr>
E-602  +  cemiplimab<\/td>Palleon Pharmaceuticals<\/td>758<\/td>GLIMMER-01: Phase I\/II trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors<\/td>PD-(L)1-resistant solid tumors<\/td>The most frequent treatment-related AEs were infusion related reactions Partial response (PR) and stable disease (SD) were achieved in 1 and 6 patients, respectively.Decreases in tumor infiltrating CD163+ macrophages were evident.<\/td><\/tr>
TTFields Plus Temozolomide\/Pembrolizumab  <\/td>Novocure<\/td>591<\/td>In-situ vaccination by tumor treating fields and anti-PD-1 immunotherapy in patients with large residual GBM results in robust T cell selection and expansion, high response rate, and extended survival<\/td>Glioblastoma<\/td>Patients with biopsy-only tumors displayed a marked improvement in both progression-free survival (27.2 m), overall survival (31.6 m) and response rates (66.6%).<\/td><\/tr>
ST101<\/td>Sapience Therapeutics<\/td>991<\/td>ST101, an inhibitor of the transcription factor C\/EBP\u00df, promotes an immune-active tumor microenvironment in a window of opportunity (WoO) study of patients with glioblastoma (GBM)<\/td>Gliolastoma<\/td>4\/6 rGBM patients show DC and 50% 6-month PFS, and 5\/6 newly diagnosed GBM patients showed DC.Increase in the M1\/M2 ratio of TAMs in resected recurrent GBM and newly diagnosed GBM tumors.ST101 was safe and well-tolerated with no discontinuations due to AEs.<\/td><\/tr>
HBI-8000<\/td>HUYABIO International<\/td>620<\/td>HBI-8000, a class I histone deacetylase (HDAC) inhibitor, in combination with nivolumab for treatment of anti- PD(L)1-naive advanced melanoma: final analysis of study HBI-8000\u2013302<\/td>PD(L)1-naive advanced melanoma<\/td>Overall response rate was 65.8%, Clinical benefit rate was 87%.Median progression-free survival was 36.9 monthsMedian duration of response was not reached.Seventeen patients discontinued treatment due to AEs.<\/td><\/tr>
IO102-IO103 + pembrolizumab<\/td>IO Biotech<\/td>756<\/td>A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)<\/td>Metastatic non-small cell lung cancer (NSCLC)<\/td>Confirmed ORR was 48.4%Disease control rate is 80.6%.PFS at 6 months was 61%.TRAEs of any grade were reported in 29 patients with 9 grade \u22653 and 3 serious events.<\/td><\/tr>
LMY-920<\/td>Luminary Therapeutics<\/td>244<\/td>A phase 1 study of novel transposon-based BAFF CAR-T cells (LMY-920) for treatment of relapsed or refractory non-hodgkin lymphoma (NHL)<\/td>Relapsed or refractory non-hodgkin lymphoma (NHL)<\/td>Disease responses observed included one complete response (DLBCL), partial response (MCL) and stable disease (MCL).All patients experienced grade 3 or higher hematologic toxicity.There have been no dose limiting toxicities and dose escalation continues.<\/td><\/tr>
IMA203<\/td>Immatics<\/td>687<\/td>ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients<\/td>Solid tumor<\/td>TEAEs were manageable with most common events being chemotherapy-related cytopenias and mainly mild to moderate CRS.cORR in patients with melanoma was 58%.Median duration of response was 10.5 months.<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"

The Society for Immunotherapy of Cancer i.e., SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy, including data on CAR T-cell therapies, cancer vaccines, bispecific and multispecific antibodies, along with next-generation cancer vaccines. Presentations from various pharmaceutical companies such as GlaxoSmithKline, Elicio Therapeutics, Palleon Pharmaceuticals, Novocure, Sapience Therapeutics, HUYABIO International, […]<\/p>\n","protected":false},"author":8,"featured_media":27336,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[22364,22365],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-30374","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-sitc","tag-sitc-2024","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nSITC 2024 Conference Summary<\/title>\n<meta name=\"description\" content=\"SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy. Read our Article to get insights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SITC 2024 Conference Summary\" \/>\n<meta property=\"og:description\" content=\"SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy. Read our Article to get insights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-19T15:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-19T15:04:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/14142759\/trop2-inhibitors-for-cancer-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SITC 2024 Conference Summary","description":"SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy. Read our Article to get insights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary","og_locale":"en_US","og_type":"article","og_title":"SITC 2024 Conference Summary","og_description":"SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy. Read our Article to get insights.","og_url":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-19T15:03:00+00:00","article_modified_time":"2024-11-19T15:04:10+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/14142759\/trop2-inhibitors-for-cancer-treatment.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary","url":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary","name":"SITC 2024 Conference Summary","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/14142759\/trop2-inhibitors-for-cancer-treatment.png","datePublished":"2024-11-19T15:03:00+00:00","dateModified":"2024-11-19T15:04:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/90e3f864ebcfcaa34b1be0e9ae5909e1"},"description":"SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy. Read our Article to get insights.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/sitc-2024-conference-summary#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/14142759\/trop2-inhibitors-for-cancer-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/14142759\/trop2-inhibitors-for-cancer-treatment.png","width":466,"height":284,"caption":"trop2-inhibitors-for-cancer-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/90e3f864ebcfcaa34b1be0e9ae5909e1","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7f5e159702916007828000ba2479aa162e568daf1ea6bf5b637e8ed4c71407ce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f5e159702916007828000ba2479aa162e568daf1ea6bf5b637e8ed4c71407ce?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/anigam"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/03\/14142759\/trop2-inhibitors-for-cancer-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">SITC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">SITC 2024<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">SITC<\/span>","<span class=\"advgb-post-tax-term\">SITC 2024<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 19, 2024","modified":"Updated on Nov 19, 2024"},"absolute_dates_time":{"created":"Posted on Nov 19, 2024 8:33 pm","modified":"Updated on Nov 19, 2024 8:34 pm"},"featured_img_caption":"trop2-inhibitors-for-cancer-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30374"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30374\/revisions"}],"predecessor-version":[{"id":30376,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30374\/revisions\/30376"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27336"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30374"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30374"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}